Osteoporosis – a current view of pharmacological prevention and treatment
暂无分享,去创建一个
[1] G. Mundy,et al. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF–β , 1996, Nature Medicine.
[2] M. Nevitt,et al. Active Shape Modeling of the Hip in the Prediction of Incident Hip Fracture , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[3] D O Slosman,et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial. , 2002, The Journal of clinical endocrinology and metabolism.
[4] Steven Boonen,et al. Testosterone and the Male Skeleton: A Dual Mode of Action , 2011, Journal of osteoporosis.
[5] J. Jansen,et al. Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies , 2009, Current medical research and opinion.
[6] B. Rovin,et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. , 2008, The New England journal of medicine.
[7] P. Roberson,et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. , 1999, The Journal of clinical investigation.
[8] C. Cooper,et al. Antidepressant medications and osteoporosis. , 2012, Bone.
[9] G. Pescarmona,et al. Teriparatide increases the maturation of circulating osteoblast precursors , 2012, Osteoporosis International.
[10] Kozo Nakamura,et al. Suppressive function of androgen receptor in bone resorption , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[11] C. Christiansen,et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. , 1997, The New England journal of medicine.
[12] G. Gamble,et al. Discrepancies in predicted fracture risk in elderly people , 2013, BMJ.
[13] G. Siest,et al. Segregation analysis and variance components analysis of bone mineral density in healthy families , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[14] D. Saxena,et al. Osteonecrosis of the jaw onset times are based on the route of bisphosphonate therapy. , 2013, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.
[15] P. Geusens,et al. Osteopenia: A Diagnostic and Therapeutic Challenge , 2011, Current osteoporosis reports.
[16] M. Rogers,et al. Nitrogen‐Containing Bisphosphonates Inhibit the Mevalonate Pathway and Prevent Post‐Translational Prenylation of GTP‐Binding Proteins, Including Ras , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[17] O. Fromigué,et al. Calcium sensing receptor-dependent and receptor-independent activation of osteoblast replication and survival by strontium ranelate. , 2009, Journal of cellular and molecular medicine.
[18] Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. , 1990, The New England journal of medicine.
[19] A Hofman,et al. Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study , 2008, The Lancet.
[20] Klaus Klaushofer,et al. Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[21] M. Shlossman,et al. Calcitonin effects on isolated bone cells , 1982, Calcified Tissue International.
[22] S. Ortolani,et al. Genetics of osteoporosis , 1994, Calcified Tissue International.
[23] J Reeve,et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. , 1980, British medical journal.
[24] T. Spinks,et al. Periodic courses of human 1–34 parathyroid peptide alternating with calcitriol paradoxically reduce bone remodelling in spinal osteoporosis , 1987, European journal of clinical investigation.
[25] M. Francis,et al. Historical perspectives on the clinical development of bisphosphonates in the treatment of bone diseases. , 2007, Journal of musculoskeletal & neuronal interactions.
[26] Daniel L. Koller,et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture , 2012, Nature Genetics.
[27] B. Gelb,et al. Pycnodysostosis, a Lysosomal Disease Caused by Cathepsin K Deficiency , 1996, Science.
[28] R. Eastell,et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. , 2012, The Journal of clinical endocrinology and metabolism.
[29] T. Chambers,et al. Calcitonin alters behaviour of isolated osteoclasts , 1982, The Journal of pathology.
[30] J. Devogelaer,et al. Biologicals in Osteoporosis: Teriparatide and Parathyroid Hormone in Women and Men , 2010, Current osteoporosis reports.
[31] Rocky S Tuan,et al. Concise Review: The Clinical Application of Mesenchymal Stem Cells for Musculoskeletal Regeneration: Current Status and Perspectives , 2012, Stem cells translational medicine.
[32] Joanne L Welton,et al. Monocytes and γδ T cells control the acute‐phase response to intravenous zoledronate: Insights from a phase IV safety trial , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[33] C. Christiansen,et al. Modulatory effect of farnesyl pyrophosphate synthase (FDPS) rs2297480 polymorphism on the response to long-term amino-bisphosphonate treatment in postmenopausal osteoporosis. , 2008, Current medical research and opinion.
[34] K. Lam,et al. Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass , 2012, Nature Medicine.
[35] Eugene McCloskey,et al. FRAX and its applications to clinical practice. , 2009, Bone.
[36] L. Melton,et al. The Unitary Model for Estrogen Deficiency and the Pathogenesis of Osteoporosis: Is a Revision Needed? , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[37] T. Spector,et al. Perinatal outcome of singletons and twins after assisted conception: a systematic review of controlled studies , 2004, The New England journal of medicine.
[38] J. Mönkkönen,et al. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. , 2001, Arthritis and rheumatism.
[39] Kenji F. Tanaka,et al. A Serotonin-Dependent Mechanism Explains the Leptin Regulation of Bone Mass, Appetite, and Energy Expenditure , 2009, Cell.
[40] J. Hopper,et al. Genetic determinants of bone mass in adults. A twin study. , 1987, The Journal of clinical investigation.
[41] G. Wesolowski,et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[42] P. LoRusso,et al. Pharmacokinetics and Pharmacodynamics of Zoledronic Acid in Cancer Patients with Bone Metastases , 2002, Journal of clinical pharmacology.
[43] Sharmila Majumdar,et al. Microarchitectural deterioration of cortical and trabecular bone: Differing effects of denosumab and alendronate , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[44] O. Beirne,et al. The relationship of denosumab pharmacology and osteonecrosis of the jaws. , 2012, Oral surgery, oral medicine, oral pathology and oral radiology.
[45] D. Cocchi,et al. Invited review: Dairy intake and bone health: a viewpoint from the state of the art. , 2011, Journal of dairy science.
[46] E. Pieterman,et al. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. , 1999, Biochemical and biophysical research communications.
[48] H. Chao,et al. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women. , 2008, Maturitas.
[49] R. Parker,et al. Farnesyl diphosphate synthase: a novel genotype association with bone mineral density in elderly women. , 2007, Maturitas.
[50] U. P. S. T. Force. Screening for osteoporosis: recommendation statement. , 2011 .
[51] D P Fyhrie,et al. In vivo trabecular microcracks in human vertebral bone. , 1996, Bone.
[52] S. Cummings,et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. , 2000, The Journal of clinical endocrinology and metabolism.
[53] E. Brown,et al. The Calcium-sensing Receptor Is Involved in Strontium Ranelate-induced Osteoclast Apoptosis , 2009, Journal of Biological Chemistry.
[54] H. Sowa,et al. Assessing the effect of baseline status of serum bone turnover markers and vitamin D levels on efficacy of teriparatide 20 μg/day administered subcutaneously in Japanese patients with osteoporosis , 2013, Journal of Bone and Mineral Metabolism.
[55] Claus Christiansen,et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. , 2009, The New England journal of medicine.
[56] Carol Coupland,et al. Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study , 2012, BMJ : British Medical Journal.
[57] J. Nieves,et al. Skeletal effects of nutrients and nutraceuticals, beyond calcium and vitamin D , 2013, Osteoporosis International.
[58] J. Mönkkönen,et al. Biochemical and molecular mechanisms of action of bisphosphonates. , 2011, Bone.
[59] J. Reginster,et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. , 2005, The Journal of clinical endocrinology and metabolism.
[60] Charles Kooperberg,et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.
[61] T. Sugimoto,et al. Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women , 2012, Osteoporosis International.
[62] D. Hanley,et al. Parathyroid hormone: regulation of synthesis and secretion. , 1993, Clinical and investigative medicine. Medecine clinique et experimentale.
[63] Mark J Bolland,et al. Evaluation of the FRAX and Garvan fracture risk calculators in older women , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[64] O. Johnell,et al. Requirements for DXA for the management of osteoporosis in Europe , 2005, Osteoporosis International.
[65] R. Aspden,et al. A method for assessment of the shape of the proximal femur and its relationship to osteoporotic hip fracture , 2004, Osteoporosis International.
[66] Marcea Whitaker,et al. Bisphosphonates for osteoporosis--where do we go from here? , 2012, The New England journal of medicine.
[67] S. Perry,et al. Screening postmenopausal women for fall and fracture prevention. , 2013, Journal of geriatric physical therapy.
[68] N. Freemantle,et al. Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis , 2012, Osteoporosis International.
[69] F. Saltel,et al. Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. , 2008, Bone.
[70] L. Melton,et al. A reference standard for the description of osteoporosis. , 2008, Bone.
[71] J. Falgueyret,et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. , 2008, Bioorganic & medicinal chemistry letters.
[72] B. Walsh,et al. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. , 2000, The Journal of clinical endocrinology and metabolism.
[73] C C Glüer,et al. Simple measurement of femoral geometry predicts hip fracture: The study of osteoporotic fractures , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[74] P. Meunier,et al. Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[75] C. Xian,et al. Functions and action mechanisms of flavonoids genistein and icariin in regulating bone remodeling , 2013, Journal of cellular physiology.
[76] E. Brown,et al. Strontium Ranelate Decreases Receptor Activator of Nuclear Factor-κB Ligand-Induced Osteoclastic Differentiation In Vitro: Involvement of the Calcium-Sensing Receptor , 2010, Molecular Pharmacology.
[77] Michael C. Nevitt,et al. Fracture Risk Reduction With Alendronate in Women With Osteoporosis: The Fracture Intervention Trial , 2001 .
[78] Alejandro F. Frangi,et al. Hip fracture discrimination from dual-energy X-ray absorptiometry by statistical model registration. , 2012, Bone.
[79] Robert Langer,et al. First-in-Human Testing of a Wirelessly Controlled Drug Delivery Microchip , 2012, Science Translational Medicine.
[80] M Dioszegi,et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). , 2001, Human molecular genetics.
[81] T. Einhorn,et al. Beyond a reasonable doubt? Bisphosphonates and atypical femur fractures. , 2012, Bone.
[82] L. Assael. Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies. , 2009, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.
[83] Steven Boonen,et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. , 2007, The New England journal of medicine.
[84] Sheila J. Jones,et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[85] R. Rizzoli. Zoledronic acid for the treatment and prevention of primary and secondary osteoporosis , 2010, Therapeutic advances in musculoskeletal disease.
[86] J. Cauley,et al. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. , 2007, Bone.
[87] Agnes Grünerbl,et al. Trabecular Bone Analysis in CT and X-Ray Images of the Proximal Femur for the Assessment of Local Bone Quality , 2009, IEEE Transactions on Medical Imaging.
[88] Guoyin Feng,et al. Sclerostin Mediates Bone Response to Mechanical Unloading Through Antagonizing Wnt/β‐Catenin Signaling , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[89] P. Yelick,et al. Cloning and complete coding sequence of a novel human cathepsin expressed in giant cells of osteoclastomas , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[90] E. Schwartz,et al. Combination Teriparatide and Raloxifene Therapy for Postmenopausal Osteoporosis: Results From a 6‐Month Double‐Blind Placebo‐Controlled Trial , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[91] L. Hocking,et al. Bone remodelling at a glance , 2011, Journal of Cell Science.
[92] H. Macdonald,et al. Women with previous fragility fractures can be classified based on bone microarchitecture and finite element analysis measured with HR-pQCT , 2013, Osteoporosis International.
[93] S. M. Arija,et al. Biochemical Markers in Osteoporosis: Usefulness in Clinical Practice , 2012 .
[94] D. Findlay,et al. Calcitonin: Physiology or fantasy? , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[95] N. D. Nguyen,et al. Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks , 2008, Osteoporosis International.
[96] S. Silverman,et al. Bisphosphonate‐Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[97] C. Poulter,et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. , 2001, The Journal of pharmacology and experimental therapeutics.
[98] J. Bilezikian,et al. Sclerostin: Therapeutic Horizons Based Upon Its Actions , 2012, Current Osteoporosis Reports.
[99] G. Bilbe,et al. Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone. , 1995, Biochemical and biophysical research communications.
[100] O. Fromigué,et al. Calcium sensing receptor‐dependent and receptor‐independent activation of osteoblast replication and survival by strontium ranelate , 2009 .
[101] B. Clarke,et al. Normal bone anatomy and physiology. , 2008, Clinical journal of the American Society of Nephrology : CJASN.
[102] R. Marx,et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. , 2005, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.
[103] D. Reid,et al. Nutrition and bone: is there more to it than just calcium and vitamin D? , 2001, QJM : monthly journal of the Association of Physicians.
[104] E. Andrews,et al. The US Postmarketing Surveillance Study of Adult Osteosarcoma and Teriparatide: Study Design and Findings From the First 7 Years , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[105] O. Bruyère,et al. Non-pharmacological management of osteoporosis: a consensus of the Belgian Bone Club , 2011, Osteoporosis International.
[106] E. Barrett-Connor,et al. Adult Weight Change and Risk of Postmenopausal Breast Cancer , 2006, The New England journal of medicine.
[107] Julian Peto,et al. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer , 1997, The Lancet.
[108] J. Reginster,et al. Adverse drug reactions to osteoporosis treatments , 2011, Expert review of clinical pharmacology.
[109] J. Pasco,et al. The population burden of fractures originates in women with osteopenia, not osteoporosis , 2006, Osteoporosis International.
[110] O. Kennedy,et al. Activation of resorption in fatigue-loaded bone involves both apoptosis and active pro-osteoclastogenic signaling by distinct osteocyte populations. , 2012, Bone.
[111] D. D. de Luis,et al. Odanacatib, a New Drug for the Treatment of Osteoporosis: Review of the Results in Postmenopausal Women , 2010, Journal of osteoporosis.
[112] J. Caverzasio. Strontium ranelate promotes osteoblastic cell replication through at least two different mechanisms. , 2008, Bone.
[113] J. Kanis,et al. Pitfalls in the external validation of FRAX , 2012, Osteoporosis International.
[114] K. Ng. Potential role of odanacatib in the treatment of osteoporosis , 2012, Clinical interventions in aging.
[115] Y. Isogai,et al. Osteosarcoma in Sprague-Dawley rats after long-term treatment with teriparatide (human parathyroid hormone (1-34)). , 2012, The Journal of toxicological sciences.
[116] E. Torres,et al. Actualización sobre la determinación de marcadores de remodelado óseo , 2003 .
[117] R. Aspden,et al. Can we improve the prediction of hip fracture by assessing bone structure using shape and appearance modelling? , 2013, Bone.
[118] Bjarni V. Halldórsson,et al. New sequence variants associated with bone mineral density , 2009, Nature Genetics.
[119] Hang Lee,et al. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. , 2010, The Journal of clinical endocrinology and metabolism.
[120] C. Moran,et al. Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals. , 2012, The Journal of bone and joint surgery. British volume.
[121] E. Posvar,et al. Single‐dose, placebo‐controlled, randomized study of AMG 785, a sclerostin monoclonal antibody , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[122] S. Boonen,et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. , 2008, The Journal of clinical endocrinology and metabolism.
[123] M. Rogers,et al. The regulation of osteoclast function and bone resorption by small GTPases , 2011, Small GTPases.
[124] R. Russell,et al. Diphosphonates and Page's disease of bone. , 1971, Lancet.
[125] R. Burge,et al. Fractures in women treated with raloxifene or alendronate: a retrospective database analysis , 2013, BMC Women's Health.
[126] P. Fratzl,et al. Microcracks and Osteoclast Resorption Activity In Vitro , 2012, Calcified Tissue International.
[127] K. Walker-Bone. Recognizing and treating secondary osteoporosis , 2012, Nature Reviews Rheumatology.
[128] J. Riancho,et al. Common allelic variants of the farnesyl diphosphate synthase gene influence the response of osteoporotic women to bisphosphonates , 2010, The Pharmacogenomics Journal.
[129] D. Kiel,et al. Risk Factors for Longitudinal Bone Loss in Elderly Men and Women: The Framingham Osteoporosis Study , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[130] Ernest K. Poku,et al. Developing Novel Prognostic Biomarkers for Multivariate Fracture Risk Prediction Algorithms , 2012, Calcified Tissue International.
[131] M. Bouxsein,et al. Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[132] B. Gertz,et al. Clinical pharmacology of alendronate sodium , 2005, Osteoporosis International.
[133] Scott M Smith,et al. Rapidly assessing changes in bone mineral balance using natural stable calcium isotopes , 2012, Proceedings of the National Academy of Sciences.